Tags

Type your tag names separated by a space and hit enter

Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Drug Test Anal. 2013 Nov-Dec; 5(11-12):843-9.DT

Abstract

Insulin-like growth factor-I (IGF-I) is reportedly misused by elite athletes, either alone or with growth hormone (GH). The GH-2000 and GH-2004 research groups previously developed a method for detecting GH misuse based on the GH-sensitive markers IGF-I and procollagen type III amino-terminal propeptide (P-III-NP). Both markers increase in response to rhIGF-I/rhIGF binding protein-3 (rhIGFBP-3) administration in recreational athletes. The aim of this pilot study was to assess the effect of rhIGF-I/rhIGFBP-3 administration on other serum markers of the GH-IGF axis and on other bone and collagen markers. Twenty-six female and 30 male recreational athletes were randomized to 28 days' treatment with placebo or rhIGF-I/rhIGFBP-3 complex, followed by 56 days' washout. GH-IGF axis markers (IGFBP-2, IGFBP-3, acid-labile subunit (ALS) and IGF-II) and bone and collagen markers (procollagen type I carboxy-terminal propeptide (PICP), type I collagen cross-linked carboxy-terminal telopeptide (ICTP) and osteocalcin) were measured using commercial immunoassays. In women in the high dose treatment group, mean IGF-II decreased by 53% (P=0.0028) on Day 21. Mean IGFBP-2 increased by 119% (P=0.0039) and mean ALS decreased by 40% (P=0.0022) on Day 21. There were no significant changes in IGFBP-3, osteocalcin, ICTP or PICP. In men in the high dose group, mean IGF-II decreased by 51% on Day 21 (P<0.0001). Mean IGFBP-2 increased by 125% on Day 21 (P=0.0003). There were no significant changes in IGFBP-3, ALS, osteocalcin, ICTP or PICP. Serum IGFBP-2 and IGF-II may be useful markers of rhIGF-I/rhIGFBP-3 administration in both women and men while ALS may also be a useful marker in women; these markers are now undergoing further evaluation.

Authors+Show Affiliations

Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24173773

Citation

Guha, Nishan, et al. "Biochemical Markers of Recombinant Human Insulin-like Growth factor-I (rhIGF-I)/rhIGF Binding Protein-3 (rhIGFBP-3) Misuse in Athletes." Drug Testing and Analysis, vol. 5, no. 11-12, 2013, pp. 843-9.
Guha N, Erotokritou-Mulligan I, Nevitt SP, et al. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes. Drug Test Anal. 2013;5(11-12):843-9.
Guha, N., Erotokritou-Mulligan, I., Nevitt, S. P., Francis, M., Bartlett, C., Cowan, D. A., Bassett, E. E., Sönksen, P. H., & Holt, R. I. (2013). Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes. Drug Testing and Analysis, 5(11-12), 843-9. https://doi.org/10.1002/dta.1562
Guha N, et al. Biochemical Markers of Recombinant Human Insulin-like Growth factor-I (rhIGF-I)/rhIGF Binding Protein-3 (rhIGFBP-3) Misuse in Athletes. Drug Test Anal. 2013 Nov-Dec;5(11-12):843-9. PubMed PMID: 24173773.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes. AU - Guha,Nishan, AU - Erotokritou-Mulligan,Ioulietta, AU - Nevitt,Simon P, AU - Francis,Michael, AU - Bartlett,Christiaan, AU - Cowan,David A, AU - Bassett,E Eryl, AU - Sönksen,Peter H, AU - Holt,Richard I G, Y1 - 2013/10/31/ PY - 2013/05/31/received PY - 2013/08/16/revised PY - 2013/09/05/accepted PY - 2013/11/1/entrez PY - 2013/11/1/pubmed PY - 2014/8/26/medline KW - Growth Hormone KW - IGF-I KW - doping KW - markers KW - misuse SP - 843 EP - 9 JF - Drug testing and analysis JO - Drug Test Anal VL - 5 IS - 11-12 N2 - Insulin-like growth factor-I (IGF-I) is reportedly misused by elite athletes, either alone or with growth hormone (GH). The GH-2000 and GH-2004 research groups previously developed a method for detecting GH misuse based on the GH-sensitive markers IGF-I and procollagen type III amino-terminal propeptide (P-III-NP). Both markers increase in response to rhIGF-I/rhIGF binding protein-3 (rhIGFBP-3) administration in recreational athletes. The aim of this pilot study was to assess the effect of rhIGF-I/rhIGFBP-3 administration on other serum markers of the GH-IGF axis and on other bone and collagen markers. Twenty-six female and 30 male recreational athletes were randomized to 28 days' treatment with placebo or rhIGF-I/rhIGFBP-3 complex, followed by 56 days' washout. GH-IGF axis markers (IGFBP-2, IGFBP-3, acid-labile subunit (ALS) and IGF-II) and bone and collagen markers (procollagen type I carboxy-terminal propeptide (PICP), type I collagen cross-linked carboxy-terminal telopeptide (ICTP) and osteocalcin) were measured using commercial immunoassays. In women in the high dose treatment group, mean IGF-II decreased by 53% (P=0.0028) on Day 21. Mean IGFBP-2 increased by 119% (P=0.0039) and mean ALS decreased by 40% (P=0.0022) on Day 21. There were no significant changes in IGFBP-3, osteocalcin, ICTP or PICP. In men in the high dose group, mean IGF-II decreased by 51% on Day 21 (P<0.0001). Mean IGFBP-2 increased by 125% on Day 21 (P=0.0003). There were no significant changes in IGFBP-3, ALS, osteocalcin, ICTP or PICP. Serum IGFBP-2 and IGF-II may be useful markers of rhIGF-I/rhIGFBP-3 administration in both women and men while ALS may also be a useful marker in women; these markers are now undergoing further evaluation. SN - 1942-7611 UR - https://www.unboundmedicine.com/medline/citation/24173773/Biochemical_markers_of_recombinant_human_insulin_like_growth_factor_I__rhIGF_I_/rhIGF_binding_protein_3__rhIGFBP_3__misuse_in_athletes_ L2 - https://doi.org/10.1002/dta.1562 DB - PRIME DP - Unbound Medicine ER -